Journal
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 21, Issue 5, Pages 295-300Publisher
HINDAWI LTD
DOI: 10.1155/2007/419784
Keywords
amoxicillin; bismuth; Canada; clarithromycin; eradication; Helicobacter pylori; meta-analysis; metronidazole; proton pump inhibitors; RCT; treatment
Categories
Ask authors/readers for more resources
BACKGROUND AND AIM: Helicobacter pylori treatment success rates have varied. A systematic review of the success rate of anti-H pylori therapy in Canada was performed. METHODS: All clinical trials containing Canadian data on the success rate of H pylori treatment were identified using MEDLINE searches, through review of references of retrieved studies and by contacting key investigators. Both randomized and open-label trials were included. Treatment effect size was calculated using a variation of Cochran's Q method. RESULTS: Seventeen papers met the inclusion criteria. Both triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole performed well, achieving a success rate of 84% and 82%, respectively. The cure rate of PPI-amoxicillin + metronidazole was 76%. Quadruple therapy consisting of a PPI, bismuth, metronidazole and tetracycline, given for seven to 10 days, achieved a success rate of 87%. CONCLUSION: Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylon infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available